Optic IconOptic Logo
|
SearchCollectionsBenchmarks
Clinical trial

Express Testing and Same-day Initiation of PrEP

ID
Name
IN-CA-412-6433
Description
This study is an observational cohort study to measure the impact of express testing and same-day initiation of Pre-Exposure Prophylaxis (PrEP) on outcomes related to the PrEP cascade. The investigators expect that same day initiation for PrEP will improve PrEP uptake. The investigators hypothesize that baseline HIV test positivity will be higher than that of general testing for gbMSM in Ontario. This is a key indicator to determine whether this targeted approach is able to access the highest risk population.
Trial arms
Trial start
2023-01-24
Estimated PCD
2024-11-30
Trial end
2024-11-30
Status
Active (not recruiting)
Treatment
Descovy
Descovy is a once-daily prescription medicine for adults and adolescents at risk of HIV. It helps lower the chances of getting HIV through sex. In this study, patients at risk of acquiring HIV will be screened for HIV and those that are HIV-negative will be initiated on PrEP within 24 hours.
Arms:
gbMSM
Other names:
emtricitabine 200 mg/tenofovir alafenamide 25 mg
Size
816
Primary endpoint
Uptake of PrEP in a rapid, same day treatment initiation setting.
January 2023 to January 2024
Eligibility criteria
Inclusion Criteria: Patients 16 years of age and older, visiting HQ for express testing, HIV negative and not currently on PrEP. Exclusion criteria: Patients under the age of 16 years of age, currently on PrEP, or living with HIV.
Protocol
{'studyType': 'OBSERVATIONAL', 'patientRegistry': False, 'designInfo': {'observationalModel': 'COHORT', 'timePerspective': 'PROSPECTIVE'}, 'enrollmentInfo': {'count': 816, 'type': 'ESTIMATED'}}
Updated at
2024-03-29

1 organization

1 product

1 indication

Organization
HQ Toronto
Product
Descovy
Indication
HIV